Innate Pharma (NASDAQ:IPHA) Trading Down 1.1% - Here's Why

Innate Pharma S.A. (NASDAQ:IPHA - Get Free Report)'s share price fell 1.1% during mid-day trading on Monday . The company traded as low as $2.13 and last traded at $2.16. 7,065 shares were traded during mid-day trading, a decline of 96% from the average session volume of 187,197 shares. The stock had previously closed at $2.18.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and issued a $11.00 price objective (down previously from $11.50) on shares of Innate Pharma in a report on Thursday, April 24th.

Innate Pharma Stock Up 2.8%

The business's fifty day moving average is $2.03 and its two-hundred day moving average is $1.93.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.